[Adjuvant chemotherapy for breast cancer].
The risk of occult micrometastasis is best predicted by axillary staging and possibly by the estrogen receptor status of the primary tumors. Adjuvant chemotherapy should be given to patients with high risk of recurrence and the drugs for adjuvant chemotherapy should be useful enough for the treatment of even advanced recurrent breast cancer. Chemohormonal therapy, especially in ER+ patients, is thought to be one of the effective measures for adjuvant therapy. There is no proof the risk of second neoplasm under adjuvant chemotherapy but can not be neglected.